NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
74.23
+0.66 (+0.90%)
At close: 4:02PM EDT

74.23 -0.01 (-0.01%)
After hours: 4:02PM EDT

Stock chart is not supported by your current browser
Previous Close73.57
Open74.65
Bid73.50 x 2200
Ask76.00 x 1200
Day's Range74.08 - 74.65
52 Week Range73.21 - 94.19
Volume1,440,143
Avg. Volume1,696,471
Market Cap191.559B
Beta0.87
PE Ratio (TTM)21.76
EPS (TTM)3.41
Earnings DateN/A
Forward Dividend & Yield2.98 (3.93%)
Ex-Dividend Date2018-03-06
1y Target Est88.16
Trade prices are not sourced from all markets
  • 2 High-Flying Biotech Stocks With Even More Room to Grow
    Motley Fool8 hours ago

    2 High-Flying Biotech Stocks With Even More Room to Grow

    These two red-hot biotechs are showing no signs of slowing down.

  • Don't Get Too Excited About PTC Therapeutics (Yet)
    Motley Fool11 hours ago

    Don't Get Too Excited About PTC Therapeutics (Yet)

    PTC Therapeutics shares are spiking following intriguing trial data; however, it's not the only competitor working on better treatments for SMA.

  • Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis
    Zacksyesterday

    Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

    Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

  • S&P 500’s Top Losses: Why Biogen Declined
    Market Realistyesterday

    S&P 500’s Top Losses: Why Biogen Declined

    The S&P 500’s top losses on June 18 were: Biogen (BIIB) declined 5.2%. Comcast Corp A (CMCSA) declined 3.8%. AmerisourceBergen (ABC) declined 3.5%. Intel (INTC) declined 3.4%. CVS (CVS) declined 3.4%. Biogen    

  • Reuters2 days ago

    Roche SMA drug shines in study as costly new therapies advance

    A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive. PTC Therapeutics, which struck a licensing deal with Roche in 2011 for its SMA programme, said more than 90 percent of babies with severe Type 1 SMA given the RG7916 drug achieved a greater than four-point increase in a test to measure their neuromuscular progress six months after treatment began. Novartis is also quickly advancing in the SMA field with its $8.7 billion acquisition this year of U.S.-based Avexis that is working on a gene therapy for the disorder.

  • Novartis Announces Positive Data on CAR-T Therapy, Kymriah
    Zacks2 days ago

    Novartis Announces Positive Data on CAR-T Therapy, Kymriah

    Novartis (NVS) announces positive results on Kymriah from the JULIET TRIAL in patients with relapsed or refractory diffuse large B-cell lymphoma.

  • Does Novartis AG (NYSE:NVS) Have A Place In Your Portfolio?
    Simply Wall St.5 days ago

    Does Novartis AG (NYSE:NVS) Have A Place In Your Portfolio?

    Over the past 10 years Novartis AG (NYSE:NVS) has returned an average of 4.00% per year from dividend payouts. The company is currently worth US$191.86B, and now yields roughly 3.71%.Read More...

  • PR Newswire5 days ago

    Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life

    -- Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%) -- About two-thirds of patients ...

  • Reuters6 days ago

    Novartis touts effectiveness, safety of autoimmune drug copies

    Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases. The Swiss drugmaker said Zessly, its Remicade biosimilar, matched the original medicine for safety and efficacy at 54 weeks, including in patients who switched from the original.

  • The Wall Street Journal6 days ago

    [$$] Prosecutors Investigating Michael Cohen for Possible Illegal Lobbying

    Federal prosecutors in Manhattan are investigating whether Michael Cohen, the longtime personal lawyer for Donald Trump, illegally engaged in secret lobbying, people familiar with the investigation said, as part of the government’s broader probe into Mr. Cohen’s business dealings. In the course of that investigation, the prosecutors have contacted companies that hired Mr. Cohen as a consultant after Mr. Trump won the 2016 presidential election, including AT&T Inc. and Novartis AG, according to other people familiar with the matter.

  • Allergan (AGN) Presents Positive Data on Glaucoma Candidate
    Zacks6 days ago

    Allergan (AGN) Presents Positive Data on Glaucoma Candidate

    Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.

  • MarketWatch6 days ago

    Is the future of therapy online? Swiss drug giant Novartis thinks so

    Can online access to mental health care improve the lives of patients with schizophrenia and multiple sclerosis? Swiss drug giant Novartis and its executive director of digital therapeutics, Joris Van Dam, say yes.

  • Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study
    Zacks8 days ago

    Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study

    Allergan's (AGN) anti-CGRP candidate, atogepant, successful in mid-stage study, following positive data readouts from two phase III studies on another anti-CGRP candidate, ubrogepant.

  • Alzheimer's Research Stumbles Again: What's the Road Ahead?
    Zacks8 days ago

    Alzheimer's Research Stumbles Again: What's the Road Ahead?

    The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.

  • The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie
    Zacks9 days ago

    The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie

    The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie

  • Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant
    Zacks12 days ago

    Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant

    Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.

  • Roche Rituxan Label Expanded by FDA for Pemphigus Vulgaris
    Zacks12 days ago

    Roche Rituxan Label Expanded by FDA for Pemphigus Vulgaris

    Roche (RHHBY) obtains FDA approval for the label expansion of Rituxan for the treatment of adults with pemphigus vulgaris.

  • GlobeNewswire12 days ago

    Detailed Research: Economic Perspectives on Koninklijke Philips N.V, Corporacion America Airports S.A, BHP Billiton, HSBC Holdings plc, Weatherford International, and Novartis AG — What Drives Growth in Today's Competitive Landscape

    NEW YORK, June 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Koninklijke ...

  • A Look at Novartis Stock in May
    Market Realist14 days ago

    A Look at Novartis Stock in May

    Headquartered in Basel, Switzerland, Novartis (NVS) is a pharmaceutical company specializing in research, development, manufacturing, and marketing of a broad range of healthcare products. It reports in the following three segments: Innovative Medicines Sandoz, the generics business Alcon, the eye care business

  • The Wall Street Journal14 days ago

    [$$] The Novartis-Cohen Connection Explained

    Although other companies, including AT&T, also paid Mr. Cohen for his services, Novartis is distinguished for likely having paid more than any of the others, and it drew the attention of prosecutors at home.

  • Treasury Department Hasn't Responded to Cohen Probe Request
    Bloomberg14 days ago

    Treasury Department Hasn't Responded to Cohen Probe Request

    The U.S. Treasury Department has refused to respond to Senator Ron Wyden’s request for financial details related to payments that Swiss drugmaker Novartis AG made to Donald Trump’s lawyer Michael Cohen, a spokeswoman for the Democratic lawmaker said. Novartis is cooperating fully and provided “substantial” responses to the letter Wyden sent the company’s chief executive last month as part of a Senate Finance Committee review, according to an email from the Oregon senator’s office Wednesday.

  • Novartis Won't Be Investigated by Swiss Over Payments to Cohen
    Bloomberg14 days ago

    Novartis Won't Be Investigated by Swiss Over Payments to Cohen

    Switzerland’s top prosecutor won’t open criminal proceedings against Novartis AG over payments the Basel-based drugmaker made to Michael Cohen, the troubled lawyer for Donald Trump. After an in-depth analysis, the Office of the Attorney-General decided there was “insufficient suspicion to justify opening criminal proceedings” it said in a statement on Wednesday. The Swiss prosecutors said they consulted with the Basel Prosecutor’s Office in Novartis’s hometown, and failed to find sufficient grounds to proceed with charges into the allegations of bribery of a foreign public official or private individual.

  • Reuters14 days ago

    Swiss prosecutors will not pursue Novartis over Trump lawyer payments

    The Swiss attorney general's office (OAG) said on Wednesday it will not bring proceedings against Novartis in connection with $1.2 million in payments the Swiss drugmaker made to U.S. President Donald Trump's personal lawyer. The OAG had received a criminal complaint alleging bribery of foreign public officials by Novartis, which has said it struck a year-long contract with Trump lawyer Michael Cohen in 2017 to gain insights into the administration's thinking on healthcare issues. Novartis has since called the pact a mistake.

  • Swiss prosecutors will not pursue Novartis over Trump lawyer payments
    Reuters14 days ago

    Swiss prosecutors will not pursue Novartis over Trump lawyer payments

    The Swiss attorney general's office (OAG) said on Wednesday it will not bring proceedings against Novartis (NOVN.S) in connection with $1.2 million in payments the Swiss drugmaker made to U.S. President Donald Trump's personal lawyer. The OAG had received a criminal complaint alleging bribery of foreign public officials by Novartis, which has said it struck a year-long contract with Trump lawyer Michael Cohen in 2017 to gain insights into the administration's thinking on healthcare issues. Novartis has since called the pact a mistake.

  • ASCO Ends: Winners & Losers at the Key Cancer Research Event
    Zacks14 days ago

    ASCO Ends: Winners & Losers at the Key Cancer Research Event

    The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.